Qingwen Zhu

Dr. Qingwen Zhu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RZRuyue Zhang
Ruyue Zhang
DZDaidi Zhang
Daidi Zhang
FHFugen Han
Fugen Han
XSXiaorui Song
Xiaorui Song
YZYaodong Zhang
Yaodong Zhang
YQYanru Qin
Yanru Qin
Background: Rhabdomyosarcoma (RMS) is a rare malignancy and the most common soft tissue sarcoma in children. Vasculogenic mimicry (VM) is a novel tumor microcirculation model different from traditional tumor angiogenesis, which does not rely on endothelial cells to provide sufficient blood supply for tumor growth. In recent years, VM has been confirmed to be closely associated with tumor progression. However, the ability of RMS to form VM has not yet been reported. Methods: Immunohistochemistry, RT-qPCR and western blot were used to test the expression level of SNAI2 and its clinical significance. The biological function in regulating vasculogenic mimicry and malignant progression of SNAI2 was examined both in vitro and in vivo. Mass spectrometry, co-immunohistochemistry, immunofluorescence staining, and ubiquitin assays were performed to explore the regulatory mechanism of SNAI2. Results: Our study indicated that SNAI2 was abnormally expressed in patients with RMS and RMS cell lines and promoted the proliferation and metastasis of RMS. Through cell tubule formation experiments, nude mice Matrigel plug experiments, and immunohistochemistry (IHC), we confirmed that RMS can form VM and that SNAI2 promotes the formation of VM. Due to SNAI2 is a transcription factor that is not easily drugged, we used Co-IP combined with mass spectrometry to screen for the SNAI2-binding protein USP7 and TRIM21. USP7 depletion inhibited RMS VM formation, proliferation and metastasis by promoting SNAI2 degradation. We further demonstrated that TRIM21 is expressed at low levels in human RMS tissues and inhibits VM in RMS cells. TRIM21 promotes SNAI2 protein degradation through ubiquitination in the RMS. The deubiquitinase USP7 and E3 ligase TRIM21 function in an antagonistic rather than competitive mode and play a key role in controlling the stability of SNAI2 to determine the VM formation and progression of RMS. Conclusion: Our findings reveal a previously unknown mechanism by which USP7 and TRIM21 balance the level of SNAI2 ubiquitination, determining RMS vasculogenic mimicry, proliferation, and migration. This new mechanism may provide new targeted therapies to inhibit the development of RMS by restoring TRIM21 expression or inhibiting USP7 expression in RMS patients with high SNAI2 protein levels.

23 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
XZXinyu Zhang
Xinyu Zhang
KZKe Zhou
Ke Zhou
KTKeyong Tian
Keyong Tian
QZQingwen Zhu
Qingwen Zhu
WLWei Liu
Wei Liu
DZDingjun Zha
Dingjun Zha
Spiral ganglion neurons (SGNs) are important for hearing, and their peripheral and central processes connect sensory cells of the Corti organ to the central nervous system. The resulting network forms a point-to-point auditory conduction. As a cardiac hormone, brain natriuretic peptide (BNP) binds to natriuretic peptide receptor type A leading to diuresis, vasodilatation, inhibition of renin and aldosterone production, and cardiac and vascular myocyte growth. This study primarily aimed to explore the expression and function of BNP in the rat’s inner ear and elucidate its regulatory mechanism. We determined the expression and function of BNP and found that the vitamin D receptor (VDR) could upregulate the expression of BNP and enhance its function. In SGNs of the rat inner ear, BNP promotes neuron survival and prolongs neurite length through the cGMP-PKG signaling pathway, which could be regulated by VDR and provide a novel approach for neuronal regeneration therapy. To the best of our knowledge, this is the first study to report this potential transcriptional regulatory relationship and will act as a reference for research on neuronal regeneration therapy for SGNs injury.

25 August 2026 in Frontiers in Allergy
Verified
Journal Article
Open access
PDF file
LWLili Wang
Lili Wang
MZMinghui Zhou
Minghui Zhou
SYShanpeng Yuan
Shanpeng Yuan
YJYang Jiao
Yang Jiao
LWLuping Wang
Luping Wang
QZQingwen Zhu
Qingwen Zhu
Background: Difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) may remain uncontrolled after adequate endoscopic sinus surgery and guideline-directed postoperative therapy. Obstructive edematous or polypoid tissue in the operated sinus cavity may limit topical corticosteroid access and delay mucosal recovery. We evaluated whether an intensified outpatient strategy—targeted in-office endoscopic debridement followed by supine head-hanging budesonide instillation—was associated with earlier recorded postoperative cavity epithelialization. Methods: This single-center retrospective cohort included 102 adults treated from January 2020 to January 2025 and reassessed against EPOS 2020 difficult-to-treat criteria. Fifty-two patients received the intensified strategy, and 50 received conventional budesonide nasal spray; both groups received the same 7-day oral methylprednisolone course. The primary endpoint was recorded postoperative cavity epithelialization at 12 weeks. Secondary endpoints included 8-week epithelialization, time to first recorded epithelialization, symptom and Lund-Kennedy score improvement, exploratory adjusted association with 12-week epithelialization, and adverse events documented in records. Because the intensified strategy comprised multiple co-delivered components, the study evaluated the overall strategy, not individual components. Results: Epithelialization by week 8 was recorded in 43/52 (82.69%) intensified-strategy patients and 20/50 (40.00%) conventional-strategy patients ( P < 0.001). Twelve-week epithelialization was recorded in 46/52 (88.46%) and 32/50 (64.00%) patients, respectively (risk difference, 24.46 percentage points; 95% CI, 8.57–40.35; risk ratio, 1.38; 95% CI, 1.10–1.74; P = 0.004). Median time to first recorded epithelialization was 4 versus 12 weeks (log-rank P < 0.001). Holm-adjusted comparisons favored the intensified strategy for symptom and endoscopic score improvements. In exploratory Firth regression, the intensified strategy remained associated with 12-week epithelialization (adjusted OR, 5.58; 95% CI, 1.87–16.68; P = 0.002). Serious adverse events were not documented, but safety assessment was retrospective and incomplete. Conclusion: In adults with postoperative difficult-to-treat CRSwNP, the intensified outpatient strategy was associated with earlier and more frequent recorded postoperative cavity epithelialization than conventional budesonide nasal spray. These findings indicate a strategy-level association and do not isolate component effects or establish comparative safety. The 12-week endpoint reflects early recorded epithelialization and does not establish durable disease control or recurrence prevention. Prospective component-controlled or factorial studies with follow-up of at least 12 months are needed.